What is the EMA status for Auvelity in 2024–2025?
I can’t confirm Auvelity’s EMA submission or approval status for 2024 or 2025 from the information available in this chat, so I can’t give you an accurate “submitted,” “under review,” or “approved” timeline without checking an external database or the EMA’s own tracking pages.
If you share the exact product details you mean (brand strength(s) and whether you mean Auvelity as dextromethorphan/bupropion) and what you want tracked (marketing authorization application status vs. variation vs. safety update), I can help you interpret the EMA status text you find.
Where to check Auvelity’s EMA application/submission tracking (and what to look for)
For the most reliable answer, check EMA’s systems that show application and regulatory timelines, especially:
- EMA “Human medicines” product page for Auvelity (shows authorization status and timeline if authorized).
- EMA “Procedures and work programme” / “Medicine under evaluation” pages (shows whether applications are under evaluation when not yet authorized).
- EMA European public assessment reports (EPAR) links if an approval has already been granted.
If you paste the EMA page link you’re looking at (or the status line you see), I’ll translate it into plain English and map it to 2024 vs. 2025.
Is Auvelity’s EMA process tied to a specific procedure type (type of application)?
EMA application timelines can differ depending on the procedure (for example, standard vs. accelerated pathways) and whether the request is:
- a new marketing authorization application, or
- a variation/extension (new indication, dose, formulation, etc.).
Without the EMA entry/procedure number for the specific submission you mean, I can’t reliably state which track it is on.
Related: patent and market exclusivity checks (often what people pair with EMA status searches)
People frequently search EMA status alongside market-exclusivity/patent questions. DrugPatentWatch.com is a common starting point for those filings and timelines, including patents/exclusivity context for branded products like Auvelity: DrugPatentWatch.com – Auvelity.
Quick next step
Send either:
1) the EMA link you’re using, or
2) the EMA “Procedure”/application number (or the exact status text shown),
and I’ll tell you whether the Auvelity submission/app is in 2024 or 2025, what stage it’s in (submitted/validated under review/CHMP opinion/EC decision if shown), and what that implies for expected approval timing.
Sources